262 related articles for article (PubMed ID: 35122158)
1. Fertility sparing treatment in patients with endometrial cancer (FERT-ENC): a multicentric retrospective study from the Spanish Investigational Network Gynecologic Oncology Group (SPAIN-GOG).
Lago V; Marina T; Laseca Modrego M; Gil-Ibañez B; Rodriguez JR; Domingo J; Minig L; Padilla-Iserte P; Arencibia Sánchez O; Sala Ferichola M; Munmanny M; Martín Salamanca B; Iacoponi S; Cabrera S; Coronado P; Utrilla-Layna J; Bataller Á; Fiol G; Corbalán S; Espinosa E; Gil-Moreno A; Domingo S;
Arch Gynecol Obstet; 2022 Sep; 306(3):821-828. PubMed ID: 35122158
[TBL] [Abstract][Full Text] [Related]
2. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
[TBL] [Abstract][Full Text] [Related]
3. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer.
Novikova OV; Nosov VB; Panov VA; Novikova EG; Krasnopolskaya KV; Andreeva YY; Shevchuk AS
Gynecol Oncol; 2021 Apr; 161(1):152-159. PubMed ID: 33461741
[TBL] [Abstract][Full Text] [Related]
4. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
[TBL] [Abstract][Full Text] [Related]
5. Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
De Rocco S; Buca D; Oronzii L; Petrillo M; Fanfani F; Nappi L; Liberati M; D'Antonio F; Scambia G; Leombroni M; Dessole M; Lucidi A
Eur J Obstet Gynecol Reprod Biol; 2022 Jun; 273():90-97. PubMed ID: 35526471
[TBL] [Abstract][Full Text] [Related]
6. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
Zhao X; Niu J; Shi C; Liu Z
Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
[TBL] [Abstract][Full Text] [Related]
7. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
[TBL] [Abstract][Full Text] [Related]
8. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Ohyagi-Hara C; Sawada K; Aki I; Mabuchi S; Kobayashi E; Ueda Y; Yoshino K; Fujita M; Tsutsui T; Kimura T
Arch Gynecol Obstet; 2015 Jan; 291(1):151-7. PubMed ID: 25118836
[TBL] [Abstract][Full Text] [Related]
9. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
[TBL] [Abstract][Full Text] [Related]
10. Continued medical treatment for persistent early endometrial cancer in young women.
Cho A; Lee SW; Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT
Gynecol Oncol; 2021 Feb; 160(2):413-417. PubMed ID: 33246662
[TBL] [Abstract][Full Text] [Related]
11. Pregnancy and oncologic outcomes after fertility-sparing management for early stage endometrioid endometrial cancer.
Chae SH; Shim SH; Lee SJ; Lee JY; Kim SN; Kang SB
Int J Gynecol Cancer; 2019 Jan; 29(1):77-85. PubMed ID: 30640687
[TBL] [Abstract][Full Text] [Related]
12. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
[TBL] [Abstract][Full Text] [Related]
13. Combined Oral Medroxyprogesterone/Levonorgestrel-Intrauterine System Treatment for Women With Grade 2 Stage IA Endometrial Cancer.
Hwang JY; Kim DH; Bae HS; Kim ML; Jung YW; Yun BS; Seong SJ; Shin E; Kim MK
Int J Gynecol Cancer; 2017 May; 27(4):738-742. PubMed ID: 28346240
[TBL] [Abstract][Full Text] [Related]
14. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of levonorgestrel-releasing intrauterine device present during controlled ovarian stimulation in patients with early stage endometrioid adenocarcinoma and atypical endometrial hyperplasia after fertility-sparing treatments: 10-year experience in one tertiary hospital in China.
Yin J; Li Y; Wang H; Wang W; Gu Y; Jin Y; Deng C; Pan L
Eur J Obstet Gynecol Reprod Biol; 2023 Jan; 280():83-88. PubMed ID: 36436458
[TBL] [Abstract][Full Text] [Related]
16. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
[TBL] [Abstract][Full Text] [Related]
17. Fertility-sparing hormonal treatment in patients with stage I endometrial cancer of grade 2 without myometrial invasion and grade 1-2 with superficial myometrial invasion: Gynecologic Oncology Research Investigators coLLaborAtion study (GORILLA-2001).
Lee AJ; Yang EJ; Kim NK; Kim Y; Suh DH; Kim J; Son JH; Kong TW; Chang SJ; Hwang DW; Park SJ; Kim HS; Yoo JG; Lee SJ; Lee YY; Shim SH
Gynecol Oncol; 2023 Jul; 174():106-113. PubMed ID: 37172410
[TBL] [Abstract][Full Text] [Related]
18. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002).
Park JY; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Seong SJ; Kim TJ; Kim JW; Kim SM; Bae DS; Nam JH
Eur J Cancer; 2013 Mar; 49(4):868-74. PubMed ID: 23072814
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcomes of fertility-sparing treatment of atypical polypoid adenomyoma with medroxyprogesterone acetate.
Nomura H; Sugiyama Y; Tanigawa T; Matoda M; Kanao H; Kondo E; Takeshima N
Arch Gynecol Obstet; 2016 Jan; 293(1):177-181. PubMed ID: 26209972
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
